1. | ![]() |
Factors that Impact the Developability of Drug Candidates | ※교수자 및 학교(기관)의 사정으로 인해 서비스 중지된 차시입니다. | |
2. | ![]() |
Physiological, Biochemical, andChemical Barriers to Oral Drug Delivery | Introduction 1. Physiological Barriers to Drug Delivery 2. Biochemical Barriers to Drug Delivery |
![]() |
3. | ![]() |
Physiological, Biochemical, and Chemical Barriers to Oral Drug Delivery | 2. Biochemical Barriers to Drug Delivery 3. Chemical Barriers to Drug Delivery 4. Drug Modifications to Enhance Transport Across Biological Barriers |
![]() |
4. | ![]() |
PhysicochemicalProperties, Formulation, and Drug Delivery | 1. Physicochemical Properties 2. Formulations |
![]() |
5. | ![]() |
PhysicochemicalProperties, Formulation, and Drug Delivery | 3. Drug Delivery 1. Target Bioavailability |
![]() |
6. | ![]() |
Targeted Bioavailability: A Fresh Look at Pharmacokinetic and Pharmacodynamic Issues in Drug Discovery and Development | 1. Target Bioavailability 2. Drug Delivery Trends and Targets Related to PK and PD 3. PK?PD in Drug Discovery and Development 4. Source of Variability of Drug Response |
![]() |
7. | ![]() |
Targeted Bioavailability :A Fresh Look at Pharmacokinetic and Pharmacodynamic Issues in Drug Discovery and Development | 4. Source of Variability of Drug Response 5. Recent Development and Issues of Bio- Analytical Methodology 6.Mechanistic PK?PD Models |
![]() |
8. | ![]() |
The Role of Transporters in Drug Delivery and Excretion | 1. Drug Transport in Absorption and Excretion 2. ABC (ATP-Binding Cassette) Transporter Family |
![]() |
9. | ![]() |
The Role of Transporters in Drug Delivery and Excretion | 3. SlC (Solute Carrier) Transporter Family | ![]() |
10. | ![]() |
Intracellular Deliveryand Disposition of Small-Molecular Weight Drugs | 1. The Relationship between the Intracellular Distribution of a Drug and its Activity 2. The Relationship between the Intracellular Distribution of a Drug and its Pharmacokinetic Properties 3. Overview of Approaches to Study Intracellular Drug Disposition 4. The Accumulation of Drugs in Mitochondria, Lysosomes, and Nuclei |
![]() |
11. | ![]() |
Intellectual Property and Regulatory Issues inDrug Delivery Research | 1. Pharmaceutical Patents 2. Statutory Requirements for Obtaining a Patent 3. Patent Procurement Strategies |
![]() |
12. | ![]() |
Intellectual Property and Regulatory Issues inDrug Delivery Research | 4. Regulatory Regime 5. FDA Market Exclusivities 6. Regulatory and Patent Law Linkage |
![]() |
13. | ![]() |
Presystemic and First-Pass Metabolism | 1. Hepatic First-Pass Metabolism | ![]() |
14. | ![]() |
Pulmonary DrugDelivery: PharmaceuticalChemistry and Aerosol Technology | 1. Aerosol Technology 2. Disease Therapy |
![]() |
15. | ![]() |
Pulmonary DrugDelivery: PharmaceuticalChemistry and Aerosol Technology | 1. Aerosol Technology 2. Disease Therapy |
![]() |
![]() |
Pulmonary DrugDelivery: PharmaceuticalChemistry and Aerosol Technology | 2. Disease Therapy 3. Formulation Variables 4. Future Developments |
![]() |
|
![]() |
Transdermal Delivery of Drugs Using Patchesand Patchless Delivery Systems | 1. Transdermal Patch Delivery Systems 2. Patchless Transdermal Drug Delivery Systems |
![]() |
|
![]() |
Transdermal Delivery of Drugs Using Patchesand Patchless DeliverySystems, Prodrug Approaches toDrug Delivery | 2. Patchless Transdermal Drug Delivery Systems 3. Recent Advances in Transdermal Drug Delivery 1. Basic Concepts: Definition and Applications |
![]() |
|
![]() |
Prodrug Approaches to Drug Delivery | 1. Basic Concepts: Definition and Applications 2. Prodrug Design Considerations |
![]() |
|
![]() |
Nanoparticles as DrugDelivery Vehicles | 1. General DDV Properties 2. Organic DDVs 3. Inorganic DDVs: Metal- and Silica ]Based Systems |
![]() |
|
![]() |
Nanoparticles as DrugDelivery Vehicles | 1. General DDV Properties 2. Organic DDVs 3. Inorganic DDVs: Metal- and Silica ]Based Systems |
![]() |